All In Biotech

Drug Trial Radar · NCT07330310

A Phase 3 Trial of JKN2401 Injection in COPD

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 888 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

888

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Sep 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • JKN2401 InjectionBiological

    JKN2401 subcutaneous injection, Q4W

  • PlaceboOther

    Placebo subcutaneous injection,Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised rate of moderate or severe COPD exacerbationsTime frame: during 52 weeks of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.